{
  "extraction_date": "2025-12-23",
  "condition": "ALZHEIMER",
  "phase": "3",
  "priority": "Expansion",
  "total_studies": 7,
  "studies": [
    {
      "study_id": "CT_NCT02118701",
      "study_type": "RCT",
      "condition": "ALZHEIMER",
      "study_title": "SHARED DECISION MAKING IN LONG-TERM CARE FACILITIES",
      "citation": "ClinicalTrials.gov NCTNCT02118701",
      "publication_year": 2025,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis mentioned in study text",
        "delivery_method": "various",
        "dosing_information": "Phase NA",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "The proportion of residents whose preferences and needs, together with the related actions to meet them, are known, documented and satisfied in their 'life-and-care plans'."
        ],
        "outcome_measures": [
          "The proportion of residents whose preferences and needs, together with the related actions to meet them, are known, documented and satisfied in their 'life-and-care plans'."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT02118701",
        "enrollment": 40,
        "phase": "NA",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT02118701"
      }
    },
    {
      "study_id": "CT_NCT03886753",
      "study_type": "Clinical Trial",
      "condition": "ALZHEIMER",
      "study_title": "Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products",
      "citation": "ClinicalTrials.gov NCTNCT03886753",
      "publication_year": 2020,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis mentioned in study text",
        "delivery_method": "various",
        "dosing_information": "Phase N/A",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change in symptoms"
        ],
        "outcome_measures": [
          "Change in symptoms"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03886753",
        "enrollment": 10,
        "phase": "N/A",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03886753"
      }
    },
    {
      "study_id": "CT_NCT05477056",
      "study_type": "Clinical Trial",
      "condition": "ALZHEIMER",
      "study_title": "Quality Improvement PrecivityAD Clinician Survey (QUIP I)",
      "citation": "ClinicalTrials.gov NCTNCT05477056",
      "publication_year": 2022,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis mentioned in study text",
        "delivery_method": "various",
        "dosing_information": "Phase N/A",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "evaluate patient selection for the blood test through analysis of clinician survey responses.",
          "evaluate score interpretation for the Amyloid Probability Score (APS) through analysis of clinician survey responses."
        ],
        "outcome_measures": [
          "evaluate patient selection for the blood test through analysis of clinician survey responses.",
          "evaluate score interpretation for the Amyloid Probability Score (APS) through analysis of clinician survey responses."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT05477056",
        "enrollment": 366,
        "phase": "N/A",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05477056"
      }
    },
    {
      "study_id": "CT_NCT02792257",
      "study_type": "RCT",
      "condition": "ALZHEIMER",
      "study_title": "Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease",
      "citation": "ClinicalTrials.gov NCTNCT02792257",
      "publication_year": 2024,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Dronabinol (Marinol\u00ae)",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Symptoms of Agitation as Measured by the Pittsburgh Agitation Scale",
          "Symptoms of Agitation as Measured by the Neuropsychiatric Inventory, Clinician Version"
        ],
        "outcome_measures": [
          "Symptoms of Agitation as Measured by the Pittsburgh Agitation Scale",
          "Symptoms of Agitation as Measured by the Neuropsychiatric Inventory, Clinician Version"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT02792257",
        "enrollment": 84,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT02792257"
      }
    },
    {
      "study_id": "CT_NCT03328676",
      "study_type": "RCT",
      "condition": "ALZHEIMER",
      "study_title": "The Effect of Cannabis on Dementia Related Agitation and Aggression",
      "citation": "ClinicalTrials.gov NCTNCT03328676",
      "publication_year": 2019,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change in score of Cohen-Mansfield Agitation Inventory (CMAI)"
        ],
        "outcome_measures": [
          "Change in score of Cohen-Mansfield Agitation Inventory (CMAI)"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03328676",
        "enrollment": 64,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03328676"
      }
    },
    {
      "study_id": "CT_NCT05432206",
      "study_type": "RCT",
      "condition": "ALZHEIMER",
      "study_title": "MEDical CANnabis for Improving Symptoms During Severe DEMentia Disorders in Long-term Care Facility in Geneva",
      "citation": "ClinicalTrials.gov NCTNCT05432206",
      "publication_year": 2024,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis Sativa Oil",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Cohen-Mansfield Agitation Inventory Scale (CMAI)"
        ],
        "outcome_measures": [
          "Cohen-Mansfield Agitation Inventory Scale (CMAI)"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT05432206",
        "enrollment": 27,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05432206"
      }
    },
    {
      "study_id": "CT_NCT06570928",
      "study_type": "RCT",
      "condition": "ALZHEIMER",
      "study_title": "Use of a Cannabinoids as a Treatment Strategy for Alzheimer's Disease",
      "citation": "ClinicalTrials.gov NCTNCT06570928",
      "publication_year": 2025,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Mini Mental State Exam (MMSE)"
        ],
        "outcome_measures": [
          "Mini Mental State Exam (MMSE)"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT06570928",
        "enrollment": 72,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT06570928"
      }
    }
  ],
  "expansion_metadata": {
    "clinicaltrials_gov_added": 7,
    "pubmed_added": 0,
    "total_added": 7,
    "expansion_date": "2025-12-23T23:42:01.051063"
  }
}